This is an international, multi-center, one-year, randomized, prospective, double-blind,
placebo-controlled, phase III study, designed to assess the effect of two non-overlapping
dose ranges of EDS EP, administered by IV infusion once per month, on neurological symptoms
of patients with Ataxia Telangiectasia.